Pharmx Technologies Ltd Extends Exclusive NDSS Agreement for 24 Months
Pharmx locks in 24-month NDSS agreement renewal
Pharmx Technologies (ASX:PHX) has confirmed the renewal of its long-standing exclusive agreement with the National Diabetes Services Scheme (NDSS), extending one of the most embedded workflows in Australian pharmacies for a further two years.
The renewal delivers a 24-month extension to the existing arrangement, commencing 1 July 2026. The company preserved the exclusive nature of the agreement, describing it as a long-standing exclusive relationship with the NDSS rather than a newly won contract.
For investors, the significance lies in continuity. The renewal reinforces Pharmx’s position as embedded digital infrastructure within Australia’s pharmacy supply chain, keeping a high-frequency ordering workflow tied to its network for a further 24 months.
No dollar value, revenue figure, or share price impact was disclosed in the announcement. The update should be read as a reaffirmation of an existing arrangement, not a first-time contract win.
When big ASX news breaks, our subscribers know first
Why the NDSS renewal matters for Pharmx
Pharmx described NDSS ordering as “one of the most frequent and operationally embedded digital workflows in Australian pharmacies.” That frequency is central to the investment read-through, because repeated, essential workflows help keep pharmacies engaged with the Pharmx network over time.
The company noted that the renewal reflects the continued confidence of key health stakeholders in its platform. According to Pharmx, the extension reinforces:
-
Its role as essential digital healthcare infrastructure
-
Its position as an enabler of pharmacy operations at scale
-
Its contribution to national health service delivery
Understanding the NDSS and Pharmx’s platform
Its integration into pharmacy ordering means the workflow is used regularly as part of routine pharmacy operations, rather than on an occasional basis.
Pharmx is described as ANZ’s leading pharmacy ordering platform, connecting the largest network of pharmacies, suppliers, and technology vendors. The company states it facilitates approximately $20 billion in transactions annually across its ordering, eInvoicing, and analytics solutions.
The relevance for investors is durability. When a high-frequency workflow such as NDSS ordering remains integrated with the platform, it can strengthen recurring engagement across the network and support the platform’s ongoing relevance to core pharmacy operations.
| Detail | What It Means for Investors |
|---|---|
| 24-month exclusive NDSS renewal | Locked-in workflow continuity |
| Commences 1 July 2026 | Immediate continuation, no gap |
| High-frequency pharmacy workflow | Deepens platform stickiness |
| ~$20B annual platform transactions | Scale of the underlying network |
The next major ASX story will hit our subscribers first
The bigger picture for Pharmx investors
The renewal sits within the broader growth narrative Pharmx outlined in its announcement. The company states it is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes, with a strategic focus on expanding its addressable market.
Pharmx has said it leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to pursue new revenue opportunities and support healthcare outcomes across Australia and New Zealand. The extended NDSS arrangement underpins continuity of a core embedded workflow as that strategy progresses.
The Sigma Healthcare alliance, secured earlier in 2026, similarly demonstrates how Pharmx embeds itself within high-frequency supply chain workflows, with Sigma taking a 10% equity stake that signals a relationship well beyond a standard vendor arrangement.
Pharmx company statement
“This long-term renewal reflects the continued confidence of key health stakeholders in the Pharmx platform and reinforces its role as essential digital infrastructure within Australia’s healthcare supply chain.”
The announcement did not disclose financial outcomes tied to the renewal. On the detail provided, the extension secures the continuity of an operationally embedded workflow while Pharmx pursues its stated growth ambitions across the ANZ pharmacy market.
Don’t Miss the Next ASX Healthcare Tech Move
Big News Blast delivers FREE breaking ASX healthcare and tech news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.